Fluorouracil

Fluorouracil

SCHEMBL29008252

O=c1[nH]cc(Cl)c(=O)[nH]1.O=c1[nH]cc(F)c(=O)[nH]1

nearest known ligand 0.76

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

TYMS

The experimentally established mechanism targets of Fluorouracil. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.76
ALDH1A1 P00352 2/20 0.76
MAPT P10636 1/20 0.76
CYP19A1 P11511 1/20 0.76
TSHR P16473 1/20 0.76
THPO P40225 1/20 0.76
MTOR P42345 1/20 0.76
HTT P42858 1/20 0.76
HBB P68871 1/20 0.76
PMP22 Q01453 1/20 0.76
SMN1; SMN2 Q16637 1/20 0.76
DPYD Q12882 4/20 0.42
GAA P10253 1/20 0.42
ATAD2 Q6PL18 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Fluorouracil SCHEMBL3646 0.87
Fluorouracil SCHEMBL249289 0.87 MAPT (1.00) LMNAALDH1A1MAPTCYP19A1TSHR
Fluorouracil SCHEMBL10017187 0.87
SCHEMBL67366 0.87
Fluorouracil SCHEMBL11327829 0.85 MAPT (0.95) LMNAALDH1A1MAPTCYP19A1TSHR
Fluorouracil SCHEMBL7650203 0.85 MAPT (0.95) LMNAALDH1A1MAPTCYP19A1TSHR
Fluorouracil SCHEMBL15284932 0.85 MAPT (0.95) LMNAALDH1A1MAPTCYP19A1TSHR
Fluorouracil SCHEMBL21527805 0.85 MAPT (0.95) LMNAALDH1A1MAPTCYP19A1TSHR
Fluorouracil SCHEMBL21880166 0.85 MAPT (0.95) LMNAALDH1A1MAPTCYP19A1TSHR
Fluorouracil SCHEMBL31441196 0.85 MAPT (0.95) LMNAALDH1A1MAPTCYP19A1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116209465-A Immunooncology combination therapy with IL-2 conjugates and anti-EGFR antibodies 新索思股份有限公司 2023-06-02 CN disclosed